The LRRK2 G2019S mutation is a major genetic determinant of Parkinson’s disease (PD) across the world that occurs at an elevated frequency in Ashkenazi Jews. We determined the LRRK2 haplotypes in 77 G2019S carriers, mostly Ashkenazi Jews, and in 50 noncarrier Ashkenazi PD patients, using 16 genetic markers. A single haplotype was detected in all mutation carriers, indicating that these individuals share a common founder. Using a maximum-likelihood method, we estimate that Ashkenazi Jews with G2019S share a common ancestor who lived ∼1,830 (95% CI 1,560–2,160) years ago, around the second century, after the second Jewish Diaspora.
This is a preview of subscription content, log in to check access.
The assistance of Dr. Helena Yagev-More is gratefully acknowledged. This work was supported by grants from National Parkinson Foundation, Miami, USA, Tel Aviv Sourasky Medical Center Grant of Excellence, and Wolfson and Kahn Foundations.
The experiments were complied with the current laws of Israel, the country in which they were performed.
de Rijk MC, Launer LJ, Berger K et al (2000) Prevalence of Parkinson’s disease in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 54:S21–S23PubMedGoogle Scholar
Goldwurm S, Di Fonzo A, Simons EJ et al (2005) The G6055A (G2019S) mutation in LRRK2 is frequent in both early and late onset Parkinson’s disease and originates from a common ancestor. J Med Genet 42:e65. doi:10.1136/jmg.2005.035568CrossRefPubMedGoogle Scholar
Kachergus J, Mata IF, Hulihan M et al (2005) Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations. Am J Hum Genet 76:672–680. doi:10.1086/429256CrossRefPubMedGoogle Scholar
Lesage S, Leutenegger AL, Ibanez P et al (2005) LRRK2 haplotype analyses in European and North African families with Parkinson disease: a common founder for the G2019S mutation dating from the 13th century. Am J Hum Genet 77:330–332. doi:10.1086/432422CrossRefPubMedGoogle Scholar
Zabetian CP, Hutter CM, Yearout D et al (2006) LRRK2 G2019S in families with Parkinson disease who originated from Europe and the Middle East: evidence of two distinct founding events beginning two millennia ago. Am J Hum Genet 79:752–758. doi:10.1086/508025CrossRefPubMedGoogle Scholar
Struewing JP, Abeliovich D, Peretz T et al (1995) The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals. Nat Genet 11:198–200. doi:10.1038/ng1095-198CrossRefPubMedGoogle Scholar
Bar-Sade RB, Theodor L, Gak E et al (1997) Could the 185delAG BRCA1 mutation be an ancient Jewish mutation? Eur J Hum Genet 5:413–416PubMedGoogle Scholar
Bar-Sade RB, Kruglikova A, Modan B et al (1998) The 185delAG BRCA1 mutation originated before the dispersion of Jews in the diaspora and is not limited to Ashkenazim. Hum Mol Genet 7:801–805. doi:10.1093/hmg/7.5.801CrossRefPubMedGoogle Scholar
Goodman RM MAe, (1979) Genetic diseases among Ashkenazi Jews. New York: Raven PressGoogle Scholar